Is Letrozole (Femara) Safe While Trying to Conceive?

What Letrozole Does in Your Body and Why It Works for Fertility

Letrozole blocks aromatase, the enzyme that converts androgens into estrogen. When you take it early in your cycle, your estrogen levels drop briefly. Your pituitary gland responds by releasing more follicle-stimulating hormone (FSH), which drives one or more follicles to grow. Once you stop taking the pill, estrogen rises normally as the follicle matures, and ovulation typically follows 5 to 12 days after the last tablet.

This mechanism is fundamentally different from clomiphene citrate. Clomiphene blocks estrogen receptors throughout the cycle, which often thins the uterine lining and thickens cervical mucus. Letrozole's short half-life of approximately 45 hours means it is gone from your body well before the implantation window. The endometrium and cervical mucus are largely unaffected, which partly explains its higher live-birth rate in women with PCOS.

Why PCOS Makes Letrozole Especially Relevant

Women with PCOS have elevated androgen levels and chronically low FSH signaling. Letrozole's temporary estrogen suppression triggers a stronger FSH pulse, which is exactly what an anovulatory PCOS cycle needs. The landmark NEJM 2014 PPCОС trial (Legro et al.) randomized 750 women with PCOS and found a live-birth rate of 27.5% with letrozole compared with 19.1% with clomiphene (p = 0.007). Ovulation also occurred more frequently with letrozole: 61.7% versus 48.3% per cycle.

How Letrozole Compares Across Reproductive Life Stages

During your reproductive years, letrozole is used for anovulation, PCOS, unexplained infertility, and as an adjunct to gonadotropin protocols for IUI or IVF.

In the trying-to-conceive phase after 35 or with diminished ovarian reserve, letrozole is sometimes combined with low-dose gonadotropins to reduce the total FSH dose needed while still recruiting adequate follicles.

In perimenopause (which can overlap with fertility treatment for women over 40), letrozole is not appropriate because ovarian function is already declining, and the hormonal milieu is too variable for reliable cycle timing.

Standard Dosing and Cycle Timing

Most reproductive endocrinologists start letrozole at 2.5 mg daily on cycle days 3 through 7. If you do not ovulate or your follicle does not reach 18 to 20 mm on ultrasound, the dose is stepped up by 2.5 mg increments in subsequent cycles. The maximum dose commonly used in practice is 7.5 mg daily, though some protocols use up to 10 mg in poor responders.

Monitoring During a Letrozole Cycle

A typical monitored letrozole cycle looks like this:

• Day 2 or 3: Baseline transvaginal ultrasound and bloodwork (estradiol, FSH) to confirm no residual cysts.
• Days 3 to 7: Take letrozole tablets at the same time each day.
• Day 10 to 14: Follicle tracking ultrasound. When the leading follicle reaches 18 mm, ovulation is typically imminent or can be triggered.
• Ovulation trigger (optional): hCG 5,000 to 10,000 IU subcutaneously or intramuscularly, or leuprolide 1 mg subcutaneously, to time intercourse or IUI within 36 hours.
• Luteal phase support: Progesterone vaginal suppositories (100 to 200 mg twice daily) are added in some protocols, particularly after IUI.

Unmonitored letrozole cycles are possible but carry a small risk of multiples and give you no information about your actual response. At a minimum, a mid-cycle urine LH strip or progesterone blood test on day 21 helps confirm ovulation occurred.

Does the Day You Start Matter?

Days 3 to 7 and days 5 to 9 are both used in clinical practice. A 2007 prospective comparison found similar ovulation and pregnancy rates between the two windows, so most clinicians default to days 3 to 7 for easier scheduling. What matters most is consistency from cycle to cycle once your protocol is established.

Pregnancy and Lactation Safety: What the Data Actually Show

Letrozole is not approved for use during pregnancy and must be stopped as soon as pregnancy is confirmed. This section covers what the evidence actually says rather than what the package insert warning alone implies.

Animal Data vs. Human Data

The FDA label for letrozole carries a pregnancy warning based on animal studies showing embryo toxicity and fetal malformations at doses many times higher than those used in humans. Rat and rabbit studies used doses up to 1 mg/kg/day, producing fetal domed skulls, incomplete ossification, and increased resorptions. These are supratherapeutic doses in animals and do not directly translate to human fertility dosing of 2.5 to 7.5 mg over five days.

Human data are far more reassuring, though no randomized trial can ethically expose pregnant women to a drug once pregnancy is confirmed.

Large Prospective Human Studies

The largest and most cited human safety study is Tulandi et al. (2006), which tracked 514 infants born after letrozole conception cycles and compared them with 397 infants from natural conception. Major congenital anomaly rates were 2.4% in the letrozole group and 4.8% in the natural conception group, a difference that was not statistically significant and, if anything, numerically favored letrozole.

A subsequent meta-analysis by Kar (2012) pooled data from six studies and found no increase in major malformations compared with clomiphene or general population rates.

The NEJM 2014 Legro trial reported congenital anomalies in 1.2% of letrozole-conceived infants versus 3.0% with clomiphene, again showing no signal of increased fetal harm from letrozole.

A useful way to frame the safety evidence for your patients and readers: letrozole's short half-life means that by cycle day 14, the drug is effectively undetectable in serum. Implantation does not occur until day 20 to 26 of a typical cycle. The window of embryonic organogenesis (days 31 to 71 from last menstrual period) begins even later. This pharmacokinetic reality means fetal exposure to active drug during the vulnerable period of organogenesis is extremely unlikely when letrozole is taken only on days 3 to 7.

What to Do if You Conceive While Still Uncertain About Drug Timing

Stop letrozole immediately. Call your prescribing clinician. Do not take the next tablet even if you are mid-course. A single early pregnancy ultrasound at 6 to 8 weeks to confirm intrauterine location and fetal cardiac activity is standard. Detailed anatomy scanning at 18 to 20 weeks provides additional reassurance.

Letrozole and Breastfeeding

Do not use letrozole while breastfeeding. The LactMed database entry for letrozole notes that the drug is lipophilic and has a molecular weight (285 g/mol) consistent with transfer into breast milk. No human milk pharmacokinetic studies have been published, which means the actual infant dose is unknown.

Beyond transfer, letrozole suppresses estrogen systemically. Estrogen is required for prolactin-mediated milk synthesis; women taking letrozole while breastfeeding may experience reduced milk supply. Because letrozole is used after breast cancer to suppress estrogen, it is actively contraindicated in any lactation context.

If you are in the postpartum period and want to restart ovulation induction, you will need to wean fully before starting letrozole, and a complete menstrual cycle (confirmed by transvaginal ultrasound) should be documented before starting a monitored cycle.

Contraception During Letrozole Treatment

This point confuses many women: letrozole is a fertility drug, so why discuss contraception?

There are two scenarios where contraception is relevant. First, if you are taking letrozole to treat conditions other than infertility (such as endometriosis or as part of a breast cancer protocol) and do not want pregnancy, you must use effective non-hormonal contraception because letrozole induces ovulation. Second, if a letrozole fertility cycle does not result in pregnancy and you need a break cycle, barrier contraception prevents an unintended pregnancy from a residual follicle in the following cycle.

Women on letrozole for breast cancer recurrence prevention and who retain ovarian function should be counseled that the drug can trigger ovulation and that pregnancy is contraindicated during active breast cancer treatment. ACOG Practice Bulletin guidance on fertility preservation after cancer specifically addresses this population.

Who This Drug Is Right For (and Who It Is Not)

Women Most Likely to Benefit

• PCOS with anovulation: Letrozole is the first-line recommendation per ASRM's 2023 practice committee opinion. Women with PCOS who have a BMI <35 and no other infertility factor have the best response rates.
• Unexplained infertility: Combined with IUI, letrozole produces live-birth rates comparable with gonadotropins at lower cost and with far fewer multiples. The FASTT trial (Diamond et al., NEJM 2010) demonstrated this in a randomized setting.
• Endometriosis-associated infertility: Letrozole plus FSH protocols are used when endometriosis is mild to moderate and the tubes are patent.
• Ovulatory dysfunction after stopping hormonal birth control: Some women experience post-pill anovulation lasting several months. Letrozole can restart cycling while waiting to see if spontaneous recovery occurs, though most clinicians wait 3 to 6 months first.

Women Who Should Not Use Letrozole for Fertility

• Current pregnancy. Stop the drug and call your provider.
• Active breastfeeding. Wait until fully weaned and menstrual cycles have resumed.
• Uncontrolled thyroid disease or hyperprolactinemia. These conditions cause anovulation for a different reason. Treating the underlying disorder first is mandatory; giving letrozole over a thyroid problem will not produce reliable ovulation.
• Premature ovarian insufficiency. Women with FSH consistently above 40 IU/L and no follicular activity on ultrasound are unlikely to respond to letrozole.
• Bilateral tubal occlusion. Letrozole induces ovulation but cannot overcome mechanical obstruction. IVF is the appropriate path.
• Active estrogen-receptor-positive breast cancer being managed without oncology involvement. Letrozole is only appropriate in this context under coordinated care with the oncology team.

Female-Specific Conditions Letrozole Touches

PCOS

Already covered above as the primary indication. One nuance: women with PCOS who also have insulin resistance may have better responses when metformin is added alongside letrozole. A Cochrane review (Morley et al., 2017) found that metformin plus letrozole improved ovulation rates in women with clomiphene-resistant PCOS compared with letrozole alone.

Endometriosis

Letrozole-based protocols suppress residual endometriotic implants while also stimulating follicular development. The ESHRE endometriosis guideline supports aromatase inhibitor use in conjunction with progestins for pain management, and reproductive endocrinologists extrapolate this to fertility protocols in selected patients.

Female Pattern Hair Loss and Hormonal Acne

These are not indications for letrozole in the fertility context. Mention here because women with PCOS often have both, and they may ask whether treating acne or hair loss with anti-androgens like spironolactone could interfere with a letrozole fertility cycle. Spironolactone is teratogenic (category D) and must be stopped before any cycle where pregnancy is possible. Letrozole itself has mild androgen-sparing effects because it reduces aromatase-driven estrogen conversion, leaving more substrate available, which can theoretically worsen androgenic symptoms transiently.

Osteoporosis Risk

Letrozole used long-term for breast cancer causes significant bone loss because systemic estrogen suppression accelerates resorption. For short 5-day fertility courses, clinically meaningful bone density loss does not occur. This is reassuring for women in their late reproductive years who may already be approaching perimenopause and are concerned about bone health.

Side Effects Women Report Most Often

Side effects with 5-day fertility dosing are generally mild and self-limiting. The most commonly reported include:

• Hot flashes: Occur in approximately 12% of women during the five days of dosing and resolve once the drug clears. These are transient estrogen withdrawal symptoms.
• Headache and fatigue: Reported in roughly 5 to 10% of users during the medication days.
• Nausea: Taking letrozole at bedtime significantly reduces nausea in most women.
• Mood changes: Some women report irritability or low mood during the dosing days. This parallels the premenstrual-like estrogen dip.
• Multiple follicles: Letrozole produces twins in approximately 3 to 5% of pregnancies, compared with 7 to 8% for clomiphene. The triplet rate is <1% with standard oral dosing.

A prospective observational study (Mitwally and Casper, 2001) that first documented letrozole's fertility application reported that side effects were well tolerated and significantly less frequent than with clomiphene.

Evidence Gaps: What We Know and What Is Extrapolated

Women have been systematically under-represented in reproductive pharmacology trials, and letrozole's fertility use is entirely off-label. What this means practically:

The FDA approved letrozole in 1997 for postmenopausal breast cancer, a population with no risk of pregnancy. All fertility dosing, timing, and monitoring protocols derive from investigator-initiated trials and practice committee recommendations rather than manufacturer-sponsored studies.

Long-term follow-up data on children conceived with letrozole extend to approximately 7 to 8 years in the largest studies. Data beyond that age are extrapolated from the congenital anomaly literature and general pediatric outcomes in ART populations. No randomized trial has compared letrozole to placebo for fertility outcomes in women with unexplained infertility with a primary endpoint of child health at age 18.

The ASRM practice committee explicitly notes this evidence gap and recommends that clinicians counsel patients that letrozole fertility use is off-label and based on substantial but not definitive evidence. This honesty is part of informed consent, not a reason to avoid the drug.

Practical Steps Before Starting Letrozole

Before your first letrozole cycle, your clinical team should confirm:

1. Baseline bloodwork: FSH, LH, estradiol (day 2 or 3), AMH, TSH, prolactin, and androgen panel if PCOS is suspected.
2. Pelvic ultrasound: To assess antral follicle count and rule out fibroids or polyps that could impair implantation.
3. Partner or donor semen analysis: Letrozole cannot overcome a severe male factor. A basic semen analysis before cycle 1 prevents wasted cycles.
4. Hysterosalpingogram (HSG) or saline infusion sonogram: Particularly for women with a history of pelvic infection, prior ectopic pregnancy, or endometriosis, to confirm tubal patency.
5. Genetic carrier screening: Offered to all reproductive-age women per ACOG Committee Opinion 690.

Once these are complete and letrozole is appropriate, your first prescription will typically be for 2.5 mg on days 3 through 7 with a follow-up ultrasound around day 12 to 14.